Printer Friendly

DATASCOPE TO SUSPEND ANGIOPLASTY OPERATIONS

 DATASCOPE TO SUSPEND ANGIOPLASTY OPERATIONS
 MONTVALE, N.J., July 20 /PRNewswire/ -- Datascope Corp.


(NASDAQ: DSCP) announced that it would suspend its Angioplasty Division operations and explore options to capture the value created by its investment in this area. As a consequence, the company said it would take a non-recurring after-tax charge to net earnings in the fourth quarter ending June 30, 1992 of $2.4 million, equivalent to $0.15 per share. The company estimates its action will increase projected net earnings in fiscal year 1993 by $0.06 per share.
 Lawrence Saper, chairman and CEO of Datascope said, "We remain convinced that our INTEGRA(TM) catheter could capture a major share of the niche market now served by fixed-wire catheters. However, this outcome could be achieved profitably today only by marketing INTEGRA as part of a broad product line due to the increased competition that has emerged in the coronary angioplasty market." Under current conditions," Saper continued, "it would be too costly to finish developing and launch the range of other products we would need to be a significant player in the coronary angioplasty business."
 Datascope Corp. is a manufacturer of proprietary products for clinical health care markets in interventional cardiology, anesthesiology and cardiovascular and vascular surgery.
 -0- 7/20/92
 /CONTACT: Lawrence Saper chairman of Datascope, 201-307-5508/
 (DSCP) CO: Datascope Corp. ST: New Jersey IN: HEA SU:


SH-KW -- NY030 -- 0668 07/20/92 10:58 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:238
Previous Article:TRANSCO ENERGY VENTURES, DUKE ENERGY SIGN AGREEMENT FOR POWER PROJECT DEVELOPMENT
Next Article:DELUXE REPORTS SECOND QUARTER SALES AND EARNINGS
Topics:


Related Articles
DATASCOPE REPORTS 42 PERCENT RISE IN SECOND QUARTER NET
DATASCOPE SUBMITS VASOSEAL PRE-MARKET APPROVAL APPLICATION
DATASCOPE REPORTS FISCAL 1993 RESULTS
DATASCOPE RESPONDS TO FDA REVIEW OF VASOSEAL PMA
DATASCOPE RECEIVES APPROVABLE LETTER FOR VASOSEAL FROM FDA
DATASCOPE REPORTS HIGHER FIRST QUARTER EARNINGS AND U.S. SALES LAUNCH OF VASOSEAL
/FIRST AND FINAL ADD -- NY077 -- DATASCOPE EARNINGS/
DATASCOPE LAUNCHES VASOSEAL AT AHA
DATASCOPE REPORTS HIGHER SECOND QUARTER RESULTS
Datascope Launches CS100 Automatic Balloon Pump.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters